問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Urology

Kaohsiung Municipal Ta-Tung Hospital (在職)

Division of Urology

更新時間：2023-09-19

李經家Li, Ching-Chia
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李經家

List

41Cases

2025-12-01 - 2033-05-05

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting5Sites

2026-06-16 - 2031-09-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2021-08-01 - 2028-01-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2022-08-22 - 2026-07-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-06-30 - 2032-05-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2017-01-01 - 2021-12-31

Phase III

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Olaparib

Participate Sites
9Sites

Recruiting5Sites

Terminated4Sites

2018-07-31 - 2020-01-31

Phase III

A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Imidafenacin in Patients with Overactive Bladder

  • Condition/Disease

    Overactive Bladder

  • Test Drug

    Uritos

Participate Sites
12Sites

Terminated11Sites

2009-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2020-11-01 - 2022-03-11

Phase II

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors

  • Condition/Disease

    Non Small Cell Lung Cancer / Urothelial Cancer / Renal Cell Carcinoma / Hepatocellular Carcinoma / Melanoma

  • Test Drug

    INCB086550

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2021-06-01 - 2022-05-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB